Utility of comprehensive genomic sequencing for detecting HER2-positive colorectal cancer

Yoshifumi Shimada, Ryoma Yagi, Hitoshi Kameyama, Masayuki Nagahashi, Hiroshi Ichikawa, Yosuke Tajima, Takuma Okamura, Mae Nakano, Masato Nakano, Yo Sato, Takeaki Matsuzawa, Jun Sakata, Takashi Kobayashi, Hitoshi Nogami, Satoshi Maruyama, Yasumasa Takii, Takashi Kawasaki, Kei ichi Homma, Hiroshi Izutsu, Keisuke KodamaJennifer E. Ring, Alexei Protopopov, Stephen Lyle, Shujiro Okuda, Kohei Akazawa, Toshifumi Wakai

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

HER2-targeted therapy is considered effective for KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (CRC). In general, HER2 status is determined by the use of immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH). Comprehensive genomic sequencing (CGS) enables the detection of gene mutations and copy number alterations including KRAS mutation and HER2 amplification; however, little is known about the utility of CGS for detecting HER2-positive CRC. To assess its utility, we retrospectively investigated 201 patients with stage I-IV CRC. The HER2 status of the primary site was assessed using IHC and FISH, and HER2 amplification of the primary site was also assessed using CGS, and the findings of these approaches were compared in each patient. CGS successfully detected alterations in 415 genes including KRAS codon 12/13 mutation and HER2 amplification. Fifty-nine (29%) patients had a KRAS codon 12/13 mutation. Ten (5%) patients were diagnosed as HER2 positive because of HER2 IHC 3+, and the same 10 (5%) patients had HER2 amplification evaluated using CGS. The results of HER2 status and HER2 amplification were completely identical in all 201 patients (P <.001). Nine of the 10 HER2-positive patients were KRAS 12/13 wild-type and were considered possible candidates for HER2-targeted therapy. CGS has the same utility as IHC and FISH for detecting HER2-positive patients who are candidates for HER2-targeted therapy, and facilitates precision medicine and tailor-made treatment.

Original languageEnglish
Pages (from-to)1-9
Number of pages9
JournalHuman Pathology
Volume66
DOIs
Publication statusPublished - 08-2017

All Science Journal Classification (ASJC) codes

  • Pathology and Forensic Medicine

Fingerprint Dive into the research topics of 'Utility of comprehensive genomic sequencing for detecting HER2-positive colorectal cancer'. Together they form a unique fingerprint.

  • Cite this

    Shimada, Y., Yagi, R., Kameyama, H., Nagahashi, M., Ichikawa, H., Tajima, Y., Okamura, T., Nakano, M., Nakano, M., Sato, Y., Matsuzawa, T., Sakata, J., Kobayashi, T., Nogami, H., Maruyama, S., Takii, Y., Kawasaki, T., Homma, K. I., Izutsu, H., ... Wakai, T. (2017). Utility of comprehensive genomic sequencing for detecting HER2-positive colorectal cancer. Human Pathology, 66, 1-9. https://doi.org/10.1016/j.humpath.2017.02.004